A detailed history of Picton Mahoney Asset Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Picton Mahoney Asset Management holds 43 shares of EXEL stock, worth $1,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43
Holding current value
$1,587
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Apr 02, 2025

BUY
$25.39 - $36.46 $1,091 - $1,567
43 New
43 $1,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Picton Mahoney Asset Management Portfolio

Follow Picton Mahoney Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Picton Mahoney Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Picton Mahoney Asset Management with notifications on news.